Zylox-Tonbridge Medical Technology Co Ltd
02190
Company Profile
Business description
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB). It derives majority of its revenue from PRC.
Contact
270 Shuyun Road, Cangqian Street
Zylox-Tonbridge Industrial Park
Yuhang District, Zhejiang Province
Hangzhou
CHNT: +86 57188610082
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
925
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.30 | 66.70 | 0.77% |
| CAC 40 | 7,743.92 | 17.72 | 0.23% |
| DAX 40 | 22,636.91 | 16.95 | -0.07% |
| Dow JONES (US) | 46,124.06 | 84.41 | -0.18% |
| FTSE 100 | 9,965.16 | 71.01 | 0.72% |
| HKSE | 25,140.34 | 76.63 | 0.31% |
| NASDAQ | 21,761.89 | 184.87 | -0.84% |
| Nikkei 225 | 53,762.10 | 1,509.82 | 2.89% |
| NZX 50 Index | 12,929.30 | 227.55 | 1.79% |
| S&P 500 | 6,556.37 | 24.63 | -0.37% |
| S&P/ASX 200 | 8,534.30 | 45.70 | 0.54% |
| SSE Composite Index | 3,916.65 | 35.37 | 0.91% |